Pfizer Corporation

The Brigham and Women's Hospital, Inc.

Cornell University

Beth Israel Deaconess Medical Center, Inc.

Boston Medical Center Corporation

Eric M Bennett

Lioudmila Tchistiakova

Lidia Mosyak

Stefano V Gulla

Sreekumar R Kodangattil

Janet Elizabeth Buhlmann

Christine Huard

Juan C Almagro

Anthony Coyle

Kimberly Ann Marquette

Edward Roland Lavallie

Steven A Greenberg

James Perry Hall

Nathan Higginson-Scott

William James Jonathan Finlay

Dangshe Ma

Edmund Graziani

Lewis C Cantley

Lawrence Nathan Tumey

Isaac J Rondon

Ruth E Gimeno

Zong Sean Juo

Puja Sapra

Valerie Calabro

Stephen Berasi

Chao Bai Huang

David J Salant

Weining Lu

Jack Bikker

Xueping Fan

Irina Apostolou

L Nathan Tumey

Brooke M Emerling

Huilan Gao

Janet E Paulsen

Stephen P Soltoff

Cindy M Hodakoski

Jian Li

Brian Gaither Bates

Edward Christian Rosfjord

Georgios Poulogiannis

Hui Liu

Kiran Manohar Khandke

Edmund Idris Graziani

Kimberley Ann Marquette

Nadira Anarkali Prashad

Jame Perry Hall

The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to interferon beta (IFNβ). Such antibodies, or antigen-binding fragments thereof, are are useful for various therapeutic or diagnostic purposes.

Interferon beta antibodies and uses thereof

The present disclosure provides materials and methods for CUB domain-containing protein 1 (CDCP1)-targeted therapy.

CDCP1 antibodies and antibody drug conjugates

Disclosed herein are humanized antibodies in which human germline residues are introduces to the complementarity determining regions (CDRs) of a non-human donor antibody. Also described herein are libraries of antibody variable domains (e.g., phage-display libraries) and methods for screening for humanized antibodies.

Humanized antibodies

The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to ROBO2, as well as uses, and methods thereof.

Anti-ROBO2 antibodies, compositions, methods and uses thereof

The present invention is directed to antibodies, and antigen-binding portions thereof, engineered to introduce amino acids for site-specific conjugation. The invention relates to engineered antibody constant region (Fc, C&#x3b3;, C&#x3ba;, and C&#x3bb;) polypeptides, and portions thereof, and antibodies comprising the polypeptides. Further, the invention relates to Fc fusion proteins comprising an engineered Fc region. The invention also relates to methods and uses of the engineered antibodies and portions for, among other things, production of antibody-drug conjugate therapeutics.

Engineered antibody constant regions for site-specific conjugation and methods and uses therefor

The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to interferon beta (IFN&#x3b2;). Such antibodies, or antigen-binding fragments thereof, are useful for various therapeutic or diagnostic purposes.

The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided. The present invention also relates to a humanized antibody that specifically binds human TrkB and methods for producing and using the antibody to, inter alia, treat a hearing loss disorder.

Bispecific antibodies

Growing community of inventors

Arlington, MA, United States of America

Eric M Bennett